# To Quantify the Impact of Addition of the GAAD Score to Imaging in Patients with Chronic Liver Disease Eligible for HCC Surveillance.

> **NCT06601231** · — · RECRUITING · sponsor: **Erasmus Medical Center** · enrollment: 1000 (estimated)

## Conditions studied

- Cancer, Hepatocellular

## Interventions

- **DIAGNOSTIC_TEST:** GAAD score

## Key facts

- **NCT ID:** NCT06601231
- **Lead sponsor:** Erasmus Medical Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-18
- **Primary completion:** 2027-04-18
- **Final completion:** 2027-07
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06601231

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06601231, "To Quantify the Impact of Addition of the GAAD Score to Imaging in Patients with Chronic Liver Disease Eligible for HCC Surveillance.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06601231. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*